Login
$PGEN
$4.33 +$0.03 (0.7%) After hours

$PGEN 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Results of Operations and Financial Condition

Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance

04 Aug 2026 8-K: Results of Operations and Financial Condition

PAPZIMEOS® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflects accelerating commercial momentum and broad US adoption

24 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

13 May 2026 8-K: Results of Operations and Financial Condition

PAPZIMEOS™ launch gaining strong momentum with $21.6 million in net product revenue in the first quarter of 2026 reflecting broad-based uptake across the US

25 Mar 2026 8-K: Results of Operations and Financial Condition

Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS™ (zopapogene imadenovec-drba), the first-and-only FDA-approved treatment for adults with RRP, in August 2025

13 Nov 2025 8-K: Results of Operations and Financial Condition

PAPZIMEOS (zopapogene imadenovec-drba) received full approval by the FDA in August

17 Sep 2025 8-K: Unregistered Sales of Equity Securities

On September 15, 2025, the holders of Precigen, Inc.’s (the “Company’s” and “our”) 8.00% Series A Convertible Perpetual Preferred Stock (“Preferred Stock”) converted 79,000 shares of Preferred Stock (with an aggregate stated value of $79...

03 Sep 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE DESIGNATED AS “[***]”.

18 Aug 2025 8-K: Entry into a Material Definitive Agreement

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMISSIONS ARE DESIGNATED AS “[***]”.

18 Aug 2025 8-K: Regulation FD Disclosure

2 Forward-looking Statement This presentation contains “forward-looking” statements within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified...

30 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

14 May 2025 8-K: Results of Operations and Financial Condition

PRGN-2012 has the potential to be the first- and best-in-class treatment for RRP

19 Mar 2025 8-K: Results of Operations and Financial Condition

FDA granted priority review to Company’s BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date for August 27, 2025

16 Jan 2025 8-K: Other Events

As previously disclosed, on November 1, 2024, Precigen, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company was not in complia...

30 Dec 2024 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +4 more

1. Name of Corporation. The name of the Corporation is Precigen, Inc.

26 Dec 2024 8-K: Entry into a Material Definitive Agreement

On December 18, 2024, Precigen, Inc. (“Precigen” or the “Company”), entered into an Asset Acquisition Agreement (the “Acquisition Agreement”) with Innovator 21, LLC (“Buyer”), a Delaware limited liability company and an affiliate of Para...

14 Nov 2024 8-K: Results of Operations and Financial Condition

– Completed pre-BLA meeting with FDA with full alignment on content of BLA, including CMC module, and path for fourth quarter 2024 rolling BLA submission for PRGN-2012† in RRP under accelerated approval pathway –

07 Nov 2024 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On November 1, 2024, Precigen, Inc. (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company was not in compliance with Nasdaq Listing ...

10 Oct 2024 8-K: Termination of a Material Definitive Agreement

As previously disclosed, on April 3, 2023, Precigen, Inc. (“Precigen” or the “Company”), entered into an Amended and Restated License Agreement (the “A&R License Agreement”) with Alaunos Therapeutics, Inc. (“Alaunos”), which amended and ...

23 Sep 2024 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support